ArticleScientific reports2020
Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03603327 (Efficacy and Safety of Response Guided Treatment With Direct Acting Anti-Viral Medications for Chronic HCV Infection - A Pilot Study), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Response Guided Treatment With Direct Acting Anti-Viral Medications for Chronic HCV Infection - A Pilot Study
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Time required to achieve optimum viral load suppression with Ravidasvir/sofosbuvir in chronic hepatitis C patients with or without compensated cirrhosis.Scientific reports · 2025Trial
- Preemptive antiviral therapy in lung transplantation from hepatitis C donors results in a rapid and sustained virologic response.JTCVS open · 2023Trial
- Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin-A Randomized Controlled Clinical Trial.Viruses · 2022Trial
- Development of a Machine Learning Model to Predict Short Duration HCV Treatment Response.Journal of viral hepatitis · 2026Article
- Modeling hepatitis D virus kinetics during bulevirtide monotherapy: challenges and solutions.ArXiv · 2026Article
- Modeling Highlights the Challenge of Achieving and Maintaining Hepatitis C Virus Micro-Elimination Among People Who Inject Drugs.Open forum infectious diseases · 2026Article
- Modeling predicts shortening of DAA treatment duration to 5 weeks in individuals with recent or chronic infection with HCV RNA negativity at day 7 on treatment.The Journal of infectious diseases · 2026Article
- Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations.JHEP reports : innovation in hepatology · 2024Article
- Advances and Challenges in Managing Hepatitis D Virus: Evolving Strategies.Current hepatology reports · 2024Article
- Hepatitis D Virus and HBsAg Dynamics in the era of new Antiviral Treatments.Current gastroenterology reports · 2023Review
- Rise in alanine aminotransferase after HCV treatment is a highly sensitive screen for treatment failure.Clinical liver disease · 2023Article
- Modeling-Based Response-Guided Hepatitis C Treatment During Pregnancy and Postpartum.Open forum infectious diseases · 2023Article
- Article
- Utility of On-Treatment Viral Loads During Treatment With Direct-Acting Antivirals in Patients Infected With Chronic Viral Hepatitis C.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2022Article
- Evaluating Post-Market Adverse Events of The New Hepatitis C Therapies Using FEARS Data.Healthcare (Basel, Switzerland) · 2022Article
- Advances in Parameter Estimation and Learning from Data for Mathematical Models of Hepatitis C Viral Kinetics.Mathematics (Basel, Switzerland) · 2022Article
- Mathematical modeling suggests that entry-inhibitor bulevirtide may interfere with hepatitis D virus clearance from circulation.Journal of hepatology · 2022Article
- Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration.Open forum infectious diseases · 2022Article
- Machine learning for mathematical models of HCV kinetics during antiviral therapy.Mathematical biosciences · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 2 countries.
Funding
Abstract
The advent of direct-acting antivirals (DAAs) has transformed the landscape of hepatitis C virus (HCV) management. We aimed to prospectively (real-time) evaluate the feasibility of using a response-guided therapy approach, based on mathematical modeling of early viral kinetics, to reduce the duration of DAAs therapy. Patients were treated with DAAs according to the physicians' preference. HCV was measured at baseline and at day 2 and weeks 1, 2 and 4 after treatment initiation. The primary endpoint was the proportion of patients with sustained-virological response (SVR) at 12 and/or 24 weeks post-treatment. Twenty-nine patients (mean age 54 ± 16, 44% females, 73% with HCV genotype 1), were enrolled and all completed therapy. Treatment duration was shortened in 11 of the 29 patients (38%). SVR was achieved in 28 of the 29 patients (97%). Relapse occurred post treatment in a single case of a non-cirrhotic male with genotype 3, who was treated with sofosbuvir/velpatasvir for 6 weeks. Virus sequencing did not identify baseline or treatment emergent resistance associated substitutions. Real-time mathematical modeling of early HCV kinetics can be utilized for shortening DAAs duration in approximately 40% of patients without compromising treatment efficacy.Clinical trial registration: ClinicalTrials.gov Identifier: NCT03603327.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.